Table 4. The list of natural product derived drugs approved by FDA from 2013 to 2014 June. The natural product leads, targets and affiliations to drug productive clusters and target-site classes are provided.
| Drug | Drug Type | NP Lead | NP Lead Type | Affiliation to drug lead productive cluster | target | Affiliation to target-site class |
|---|---|---|---|---|---|---|
| Canagliflozin | Small Molecule | Phlorizin | N | Near DC57 (tanimoto similarity coefficient 0.91 to the nearest NPLD) | SGLT2 | Monosacharide transporter substrate sites as a new TC in TS12 (saccharide binding sites) |
| Luliconazole | Small Molecule | Imidazole-based NP such as mizoribine | N | DC13 | Lanosterol demethylase | Steroid metabolism enzyme substrate sites in TS19 (steroid binding sites) |
| Sofosbuvir | Small Molecule | Uridine monophosphate | N | DC5 | HCV NS5B polymerase | TC7 |
| Vorapaxar | Small molecule | Himbacine | N | - | Protease-activated receptor-1 | TC22 |
| Simeprevir | Oligopeptide | HCV NS3/4A protease product oligopeptide | B (oligopeptide) | DC9 | HCV NS3/4A protease | TC28 |
| Mipomerse | Antisense | Section of mRNA of apolipoprotein B-100 | B (oligonucleotide) | - | Apolipoprotein B-100 | Lipid-binding sites in TS15 |
| Dalvance | Semisynthetic lipoglycopeptide | Lipoglycopeptide | B (lipoglycopeptide) | - | Cell wall | TC30 |
| Tanzeum | Peptide | Glucagon-like peptide-1 | B (peptide) | - | Glucagon-like peptide-1 receptor | TC22 |